Core Viewpoint - Jilin Aodong's stock price has shown fluctuations with a year-to-date increase of 27.06%, while recent trading indicates a slight decline over the past five days [1] Financial Performance - For the period from January to September 2025, Jilin Aodong reported revenue of 1.64 billion yuan, a year-on-year decrease of 14.10%, while net profit attributable to shareholders reached 2.26 billion yuan, reflecting a significant increase of 81.70% [2] Shareholder Information - As of September 30, 2025, the number of shareholders for Jilin Aodong was 61,200, a decrease of 7.18% from the previous period, with an average of 19,456 circulating shares per shareholder, which is an increase of 7.73% [2] Dividend Distribution - Since its A-share listing, Jilin Aodong has distributed a total of 4.664 billion yuan in dividends, with 1.881 billion yuan distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, among the top ten circulating shareholders, the Southern CSI 500 ETF held 13.93 million shares, a decrease of 317,900 shares from the previous period, while the Hong Kong Central Clearing Limited held 11.82 million shares, down by 319,620 shares [3]

Core Insights - The report highlights that 44 brokerage firms have invested in 351 stocks, with a total holding value exceeding 66 billion yuan as of the end of Q3 [2][3] - High-end manufacturing and technology sectors are identified as popular investment directions for brokerages, reflecting a shift towards structural opportunities in the equity market [2][3] Brokerage Holdings Overview - The top 10 stocks held by brokerages by market value include Muyuan Foods, Guangqi Technology, and Cangge Mining, with holdings exceeding 1 billion yuan for several stocks [3][4] - The distribution of holdings indicates a strong focus on sectors such as machinery, pharmaceuticals, electronics, and basic chemicals, with the highest number of stocks in machinery equipment (35 stocks) and pharmaceuticals (28 stocks) [3][4] Trading Activity - Brokerages have entered 186 new stocks, with notable new positions including Postal Savings Bank and China Foreign Transport, each exceeding 30 million shares [4] - A total of 69 stocks saw increased holdings, particularly in the basic chemicals and transportation sectors, while 61 stocks were reduced, indicating a selective approach to portfolio management [5][4] Self-Operated Business Performance - Self-operated business remains the largest revenue contributor for brokerages, with a reported income of 186.857 billion yuan in the first three quarters, marking a 43.83% year-on-year increase [6][7] - Major brokerages like CITIC Securities and Guotai Junan reported significant growth in self-operated income, driven by a recovering equity market and strategic asset allocation [6][7] Market Trends and Analysis - Analysts note that the active trading environment and increased margin financing have positively impacted brokerage performance, with a significant rise in average daily trading volume [7] - The shift towards equity assets and the reduction in bond investments reflect a broader trend of rebalancing within the brokerage sector [7]

Core Viewpoint - The article highlights the latest holdings of securities firms in the A-share market as of the end of Q3 2025, indicating significant investment activity and sector preferences among these firms [1][5]. Holdings Overview - As of the end of Q3 2025, 44 securities firms appeared in the top ten shareholders of 361 listed companies, with a total holding value of 66.623 billion yuan [1]. - The most concentrated sectors for securities firm investments are hardware equipment and chemical industries, with 41 and 33 stocks respectively, followed by pharmaceuticals and machinery with 26 and 20 stocks [1]. Major Holdings - The top holdings by securities firms include: - CITIC Securities holds 1.3743 million shares of Muyuan Foods valued at 1.984 billion yuan [4]. - Shenwan Hongyuan has a holding of 1.2148 million shares of Guangqi Technology valued at 1.079 billion yuan [4]. - Other notable holdings include Cangge Mining and Jilin Aodong, with holdings valued at 928 million yuan and 865 million yuan respectively [2][4]. New Investments - In Q3, securities firms entered the top ten shareholders of 206 new stocks, primarily in the non-ferrous metals, pharmaceuticals, hardware equipment, and chemical sectors [5]. - Noteworthy new investments include: - Guotai Junan's entry into Postal Savings Bank with a holding valued at 727 million yuan [5]. - CITIC Securities' new position in Huayuan Ecology valued at 344 million yuan [5]. Increased Holdings - A total of 63 stocks saw increased holdings from securities firms in Q3, with significant increases in positions such as: - Dongfang Securities increased its holding in Inner Mongolia Huadian by 21.94 million shares, adding over 8.8 million yuan in value [5]. - CITIC Securities increased its position in Muyuan Foods by 507,500 shares, adding approximately 433 million yuan [5]. Decreased Holdings - Some securities firms reduced their holdings in certain stocks, such as CITIC Securities reducing its position in Xin Nuo Wei, while others like Shenwan Hongyuan reduced holdings in Guangqi Technology and Cangge Mining but saw their holding values increase due to stock price appreciation [6]. Self-operated Business Performance - The performance of securities firms' self-operated businesses is closely linked to their stock holdings, with total self-operated income reaching 186.857 billion yuan in the first three quarters of the year, accounting for over 44% of total revenue [7]. - CITIC Securities led with a self-operated income of 31.603 billion yuan, a year-on-year increase of approximately 46% [8]. Self-operated Business Breakdown - The self-operated income of major securities firms for the first three quarters includes: - CITIC Securities: 31.603 billion yuan, 45.88% year-on-year growth [8]. - Guotai Junan: 20.37 billion yuan, 90.11% year-on-year growth [8]. - Other firms like China Galaxy and Shenwan Hongyuan also reported significant self-operated income exceeding 10 billion yuan [8].

Core Viewpoint - The company, Jilin Aodong Pharmaceutical Group Co., Ltd., has disclosed its third-quarter financial report for 2025, ensuring the accuracy and completeness of the information presented [1][2][10]. Financial Data - The third-quarter financial report has not been audited [3][7]. - The company does not require retrospective adjustments or restatements of previous accounting data [3]. - There are no non-recurring profit and loss items applicable for the reporting period [3][4]. Shareholder Information - The total number of ordinary shareholders and the situation of the top ten shareholders have been reported, but there are no changes due to securities lending activities [5][6]. Board Meeting - The 19th meeting of the 11th Board of Directors was held on October 30, 2025, with all nine directors present [8][9]. - The board approved the third-quarter report and the proposal to adjust external investments and introduce strategic investors, with unanimous support [10][12][26]. Investment Adjustment - The company plans to adjust its external investments and introduce strategic investors to optimize the capital structure of its subsidiary, Aodong Pharmaceutical (Anhui) Co., Ltd. [16][22]. - The registered capital of Aodong Anhui will be reduced from 300 million yuan to 20 million yuan, with the company terminating its planned investment of 3 million yuan [18][20]. - A new strategic investor, Zhongneng Shuzhi Technology (Shanghai) Co., Ltd., will be introduced, holding 40% of the shares [20][22]. Purpose and Impact of Adjustment - The adjustment aims to focus on core business development and enhance market competitiveness, particularly in key regions like Shanghai [22]. - The company believes this adjustment will optimize resource allocation and control investment risks, aligning with its long-term strategic interests [24].

Core Viewpoint - Jilin Aodong (000623.SZ) reported a year-on-year increase in revenue and net profit for Q3 2025, indicating positive financial performance and growth potential [1] Financial Performance - The company achieved an operating revenue of 5.139 billion yuan, representing a year-on-year increase of 3.25% [1] - The net profit attributable to shareholders reached 979 million yuan, showing a significant year-on-year increase of 38.53% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 823 million yuan, reflecting a substantial year-on-year increase of 109.71% [1] - Basic earnings per share were reported at 0.835 yuan [1]

Core Insights - The company reported a revenue of 1.64 billion yuan for the first three quarters of 2025, representing a year-on-year decline of 14.10% [1] - The net profit attributable to shareholders increased to 2.26 billion yuan, showing a significant year-on-year growth of 81.70% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses reached 1.99 billion yuan, reflecting a year-on-year increase of 65.20% [1] Financial Performance - Revenue for the first three quarters: 1.64 billion yuan, down 14.10% year-on-year [1] - Net profit attributable to shareholders: 2.26 billion yuan, up 81.70% year-on-year [1] - Net profit after deducting non-recurring items: 1.99 billion yuan, up 65.20% year-on-year [1]

证券代码：000623 证券简称：吉林敖东 公告编号：2025-058 吉林敖东药业集团股份有限公司 关于对外投资调整并引入战略投资者的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 吉林敖东药业集团股份有限公司（以下简称"公司"）于 2025 年 10 月 30 日召开第十一届董事会第十九次会议审议通过了《关于对外投资调整并引入战略 投资者的议案》，为适应市场变化，优化子公司敖东药业（安徽）股份有限公司 （以下简称"敖东安徽公司"）的资本结构与战略布局，经与控股子公司吉林敖 东延边药业股份有限公司（以下简称"延边药业"）协商，拟调整对外投资并引 进战略投资者，具体公告如下： 一、对外投资概述 本次对外投资调整涉及子公司注册资本变更及引入战略投资者，本次调整不 涉及关联交易，不构成《上市公司重大资产重组管理办法》规定的重大资产重组。 1.注册资本调整 敖东安徽公司注册资本由 30,000 万元减少至 2,000 万元，减资程序按照《公 司法》相关规定执行。 1 2.出资义务调整 公司：终止原计划未实缴的 300 万元出资义务，不再持有敖东安徽公司股份。 ...

证券代码：000623 证券简称：吉林敖东 公告编号:2025-056 吉林敖东药业集团股份有限公司 第十一届董事会第十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、吉林敖东药业集团股份有限公司（以下简称"公司"）第十一届董事会 第十九次会议通知以书面方式于 2025 年 10 月 19 日发出。 2、会议于 2025 年 10 月 30 日在公司六楼会议室以现场结合通讯方式召开。 3、本次会议公司应到董事 9 名，实际参加会议董事 9 名，其中：独立董事 李鹏先生、肖维维女士、梁毕明先生以通讯表决方式出席本次会议。 4、会议由公司董事长李秀林先生主持，公司高级管理人员列席本次董事会 会议。 5、本次会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定。 二、董事会会议审议情况 1、审议《公司 2025 年第三季度报告全文》 董事会经审议认为：《公司 2025 年第三季度报告全文》的编制程序、内容 以及格式符合相关法律、法规和中国证监会规范性文件的规定和要求；公司的 财务报告真实、准确、完 ...

Financial Performance - The company's revenue for Q3 2025 was ¥513,937,810.01, an increase of 3.25% compared to the same period last year[4] - Net profit attributable to shareholders reached ¥978,957,330.73, representing a significant increase of 38.53% year-on-year[4] - The net profit excluding non-recurring gains and losses was ¥823,238,943.93, up 109.71% from the previous year[4] - Basic earnings per share were ¥0.8350, reflecting a growth of 41.31% compared to the same quarter last year[4] - Net profit attributable to shareholders of the parent company rose to ¥2,260,496,439.24, an increase of 81.70% driven by investment income and fair value changes.[9] - Net profit for the current period is ¥2,255,329,694.19, compared to ¥1,218,546,029.35 in the previous period, indicating an increase of approximately 85.1%[19] - The profit attributable to shareholders of the parent company is ¥2,260,496,439.24, up from ¥1,244,115,685.35, marking a growth of around 81.7%[19] - The total comprehensive income for the current period is ¥2,195,731,865.17, compared to ¥1,457,427,889.24, indicating an increase of approximately 50.7%[19] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥34,575,899,940.55, a 4.77% increase from the end of the previous year[4] - The company's equity attributable to shareholders increased by 5.31% to ¥30,568,244,673.71 compared to the end of last year[4] - Total assets increased to $34.58 billion from $33.00 billion, representing a growth of approximately 4.8%[17] - Current assets rose to $5.22 billion, up from $4.83 billion, indicating an increase of about 8.1%[15] - Long-term equity investments increased to $25.73 billion from $24.35 billion, reflecting a growth of approximately 5.7%[15] - Total liabilities decreased slightly to $3.76 billion from $3.72 billion, a change of about 1.1%[17] - Short-term borrowings decreased to $1.14 billion from $1.25 billion, a reduction of approximately 9.0%[17] - Accounts payable decreased to $352.15 million from $417.39 million, a decline of about 15.6%[17] - Non-current assets totaled $29.36 billion, up from $28.17 billion, indicating an increase of about 4.2%[17] - The company's retained earnings increased to $21.46 billion from $19.78 billion, reflecting a growth of approximately 8.5%[17] Cash Flow - Cash flow from operating activities for the year-to-date was ¥161,051,103.70, showing a remarkable increase of 443.63%[4] - Operating cash flow net amount improved to ¥161,051,103.70, a substantial increase of 443.63% compared to the previous period.[9] - Cash inflow from operating activities totaled ¥1,846,002,397.37, down from ¥2,149,740,908.19, a decrease of about 14.1%[20] - Cash flow from operating activities decreased from 2,196,608,043.40 to 1,684,951,293.67, a decline of approximately 23.3%[22] - Cash flow from investment activities increased by 91.28% to ¥510,339,185.26, attributed to a decrease in cash paid for investments.[9] - Cash inflow from investment activities decreased from 3,822,068,687.00 to 2,788,846,709.32, representing a drop of about 27.1%[22] - Net cash flow from financing activities showed a negative change from -672,365,438.79 to -563,265,104.30, indicating an improvement of approximately 16.3%[22] - Total cash and cash equivalents at the end of the period increased to 1,213,726,929.22 from 1,105,646,454.39, reflecting a growth of about 9.8%[22] Expenses and Income - Management expenses decreased by 31.40% to ¥142,954,141.60, attributed to enhanced internal controls[8] - Financial expenses were reduced by 50.85% to ¥29,631,579.59, primarily due to a decrease in interest expenses[8] - Investment income increased to ¥2,080,922,165.92, a year-on-year growth of 58.63% primarily due to gains from investments in GF Securities Co., Ltd.[9] - Fair value changes in financial assets resulted in a profit of ¥292,443,572.99, reflecting a significant increase of 1358.96% compared to the previous period.[9] - Credit impairment losses decreased by 86.25% to ¥-1,511,287.29, mainly due to a reduction in expected credit losses on other receivables.[9] - The company reported a significant increase in prepayments by 92.21% to ¥50,113,850.22, mainly due to prepayments to suppliers[8] - The company reported a decrease in other comprehensive income after tax to ¥-59,597,829.02, a decline of 124.95% year-on-year.[9] - The net asset disposal loss decreased by 43.37% to ¥-265,374.22, indicating improved asset management.[9] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 61,216, with no preferred shareholders restoring voting rights.[11] - The largest shareholder, Dunhua Jincheng Industrial Co., Ltd., holds 27.35% of shares, amounting to 327,080,749 shares, with 107,425,000 shares pledged.[11]

Core Insights - The traditional Chinese medicine sector saw a slight increase of 0.25% on October 29, with Jilin Aodong leading the gains [1] - The Shanghai Composite Index closed at 4016.33, up 0.7%, while the Shenzhen Component Index closed at 13691.38, up 1.95% [1] Stock Performance - Jilin Aodong (000623) closed at 21.82, with a rise of 4.95% and a trading volume of 311,200 shares, amounting to a transaction value of 672 million yuan [1] - Other notable gainers included: - Biovale (920266) at 10.41, up 3.17% [1] - Datang Pharmaceutical (920433) at 6.74, up 2.90% [1] - Kang En Bei (600572) at 4.56, up 2.47% [1] - Baiyunshan (600332) at 26.12, up 2.15% [1] Capital Flow - The traditional Chinese medicine sector experienced a net outflow of 522 million yuan from institutional investors, while retail investors saw a net inflow of 560 million yuan [2][3] - The capital flow for key stocks showed: - Jilin Aodong had a net inflow of 75.01 million yuan from institutional investors [3] - Baiyunshan had a net inflow of 25.07 million yuan from institutional investors [3] - Zhenbao Island (603567) had a net inflow of 17.41 million yuan from institutional investors [3]